EGFR and non-small cell lung carcinoma: A phase Ib trial, which recruited Japanese patients with advanced EGFR-mutated metastatic NSCLC, showed a tolerable safety profile of afatinib plus ramucirumab and a median PFS of 9.2 months [22].